WO2001079144A3 - Fyn kinase comme cible de modulation de la transduction des signaux medies par l'integrine - Google Patents

Fyn kinase comme cible de modulation de la transduction des signaux medies par l'integrine Download PDF

Info

Publication number
WO2001079144A3
WO2001079144A3 PCT/US2001/012039 US0112039W WO0179144A3 WO 2001079144 A3 WO2001079144 A3 WO 2001079144A3 US 0112039 W US0112039 W US 0112039W WO 0179144 A3 WO0179144 A3 WO 0179144A3
Authority
WO
WIPO (PCT)
Prior art keywords
src
gpiiia
phosphatases
family kinases
modulation
Prior art date
Application number
PCT/US2001/012039
Other languages
English (en)
Other versions
WO2001079144A2 (fr
Inventor
Kyra J Cowan
Debbie A Law
David R Phillips
Original Assignee
Cor Therapeutics Inc
Kyra J Cowan
Debbie A Law
David R Phillips
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cor Therapeutics Inc, Kyra J Cowan, Debbie A Law, David R Phillips filed Critical Cor Therapeutics Inc
Priority to AU2001255349A priority Critical patent/AU2001255349A1/en
Publication of WO2001079144A2 publication Critical patent/WO2001079144A2/fr
Publication of WO2001079144A3 publication Critical patent/WO2001079144A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70557—Integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une interaction directe entre des domaines cytoplasmiques GPIIIa phosphorilés dotés 1) de kinases de famille src/exemptes de src et 2) de phosphatases. Cette invention a également trait à des méthodes d'identification d'agents qui bloquent des interactions GPIIIa avec des kinases de famille src/exemptes de src et des phosphatases, des méthodes d'utilisation des agents qui bloquent des interactions GPIIIa avec des kinases de famille src/exemptes de src et des phosphatases PIP-1C afin de moduler des agents et processus biologiques et pathologiques qui bloquent une liaison médiée par GPIIIa à des kinases de famille src/exemptes de src et à des phosphatases PIP-1C, ce qui permet de moduler la signalisation afférente médiée par GPIIIa.
PCT/US2001/012039 2000-04-14 2001-04-13 Fyn kinase comme cible de modulation de la transduction des signaux medies par l'integrine WO2001079144A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001255349A AU2001255349A1 (en) 2000-04-14 2001-04-13 Fyn kinase as a target for modulation of integrin mediated signal transduction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19740300P 2000-04-14 2000-04-14
US60/197,403 2000-04-14

Publications (2)

Publication Number Publication Date
WO2001079144A2 WO2001079144A2 (fr) 2001-10-25
WO2001079144A3 true WO2001079144A3 (fr) 2002-02-28

Family

ID=22729274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012039 WO2001079144A2 (fr) 2000-04-14 2001-04-13 Fyn kinase comme cible de modulation de la transduction des signaux medies par l'integrine

Country Status (2)

Country Link
AU (1) AU2001255349A1 (fr)
WO (1) WO2001079144A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090381A1 (fr) 2004-03-24 2005-09-29 Auckland Uniservices Limited Proteines set1 et utilisations associees
US8057815B2 (en) * 2004-04-19 2011-11-15 Portola Pharmaceuticals, Inc. Methods of treatment with Syk inhibitors
EP1805210A4 (fr) * 2004-09-09 2007-10-24 Auckland Uniservices Ltd Nouveaux peptides et procédés pour le traitement de maladie inflammatoire
US20090118174A1 (en) * 2005-04-19 2009-05-07 Auckland Uniservices Limited Novel peptides and methods for the treatment of inflammatory disorders
EP2068877A4 (fr) * 2006-07-19 2011-09-21 Cleveland Clinic Foundation Composés et méthodes de modulation de l'angiogenèse
US8563690B2 (en) 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
JP6047150B2 (ja) * 2011-05-13 2016-12-21 キングス・カレッジ・ロンドン 血小板感受性に関係する方法と組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014432A1 (fr) * 1995-10-18 1997-04-24 Cor Therapeutics, Inc. Modulation de la transduction d'un signal induit par l'integrine
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
WO1998022500A2 (fr) * 1996-11-21 1998-05-28 Cor Therapeutics, Inc. Modulation d'interactions entre myosine et integrines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753687A (en) * 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
WO1997014432A1 (fr) * 1995-10-18 1997-04-24 Cor Therapeutics, Inc. Modulation de la transduction d'un signal induit par l'integrine
WO1998022500A2 (fr) * 1996-11-21 1998-05-28 Cor Therapeutics, Inc. Modulation d'interactions entre myosine et integrines

Also Published As

Publication number Publication date
AU2001255349A1 (en) 2001-10-30
WO2001079144A2 (fr) 2001-10-25

Similar Documents

Publication Publication Date Title
WO2003050295A3 (fr) Essais et mises en oeuvre permettant de determiner et de moduler une activite de liaison hsp90
WO1999048868A3 (fr) Familles heterocycliques de composes destinees a la modulation de la tyrosine-kinase
WO1998007835A3 (fr) Structures cristallines d'une proteine tyrosine kinase
AU8101698A (en) Use of fviia or fviiai for the treatment of adverse conditions related to the fviia mediated intracellular signalling pathway
BR9914599A (pt) Domìnios de ligação de ramificação de zinco paragnn
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
PL339860A1 (en) Methods of modulating the action of serine/threonine protein kinase by means of compounds based on 5-azaquinoxaline
WO2001064681A3 (fr) Composes de 3-(pyrolyllactone)-2-indolinone comme inhibiteurs des kinases
WO2005007090A3 (fr) Inhibiteurs de la voie de signalisation des map kinases
WO1998024432A3 (fr) Utilisation de composes a base d'indolinone en tant que modulateurs de proteine kinases
ATE469981T1 (de) Tests auf proteinkinasen mit fluoreszierenden proteinsubstraten
WO2001079144A3 (fr) Fyn kinase comme cible de modulation de la transduction des signaux medies par l'integrine
WO1999019513A3 (fr) Procedes pour la detection de composes modulant l'activite d'un recepteur d'acide lysophosphatidique (lpa)
WO2001064741A3 (fr) Methodes de modulation selective des voies d'apoptose regulees par la survivine
WO1999050440A3 (fr) Methode de modulation selective des interactions entre survivine et tubuline
WO1997026331A3 (fr) Utilisation de la proteine inhibitrice d'apoptose neuronale (naip)
WO1997040379A3 (fr) EPREUVES ET REACTIFS PERMETTANT L'IDENTIFICATION DE MODULATEURS D'ACTIVATION DE LA MITOSE INDUITE PAR Cdc25
WO2000008181A3 (fr) Polypeptide chp, un ligand du pak65
WO1998022500A3 (fr) Modulation d'interactions entre myosine et integrines
DE69943374D1 (de) Verfahren zur modulation der angiogenese mittels der tyrosin kinase src
DE69628936D1 (de) Test zur identifikation von inhibitoren der interaktion zwischen p53 und dm2 proteinen
WO1998049317A3 (fr) Diagnostic et traitement de troubles lies a la phosphatase ou a la kinase
WO2002066681A3 (fr) Reactifs et methodes d'identification et de modulation de l'expression de genes regules par des inhibiteurs de cdk
WO2003074007A3 (fr) Modulateurs d'activation des leucocytes, compositions, et methodes d'utilisation
WO2007019421A3 (fr) Regulation d'activite de proteine s6 kinase et procedes connexes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP